Media Summary: Combination of Encorafenib and Cetuximab With or Without Alpelisib in Patients With Advanced BRAF-Mutant (BRAFm) ... When Gary was diagnosed with cancer, his doctors recommended a clinical trial. Hear his story in the latest video by "You can't just sit back and be a spectator. You have to get into the fight and be a participant in this journey that we're all on.

Arry Array Biopharma Phase 2 - Detailed Analysis & Overview

Combination of Encorafenib and Cetuximab With or Without Alpelisib in Patients With Advanced BRAF-Mutant (BRAFm) ... When Gary was diagnosed with cancer, his doctors recommended a clinical trial. Hear his story in the latest video by "You can't just sit back and be a spectator. You have to get into the fight and be a participant in this journey that we're all on. Buffett said: He saw all the stock earnings I think the final value of the investment does not need to see numbers only need to ... Go behind the scenes and "Meet the Scientist" with Allison Marlow, PhD, a medical writer and scientist at Dr. Victor Sandor talks about the latest developments at

Photo Gallery

ARRY Array Biopharma Phase 2 Results: Encorafenib & Cetuximab - Patients With Colorectal Cancer
$ARRY - Array Biopharma Inc - Independent Analysis (2)
Array Biopharma waiting on approval for skin cancer drugs
Meet Gary - Array BioPharma
Meet Anne - Array BioPharma
$ARRY - Array Biopharma Inc - Independent Analysis
ARRY Array BioPharma Inc  ARRY buy or sell Buffett read basic
Pfizer buys Array Biopharma for $48/share in cash
PropThink Interviews: Array BioPharma
Array BioPharma Adds 10% on Positive Study Data for ARRY-520
Meet the Scientist - Array BioPharma
News Update: Analyst Downgrades Array BioPharma, Inc; Shares Plummet (NASDAQ:ARRY)
View Detailed Profile
ARRY Array Biopharma Phase 2 Results: Encorafenib & Cetuximab - Patients With Colorectal Cancer

ARRY Array Biopharma Phase 2 Results: Encorafenib & Cetuximab - Patients With Colorectal Cancer

Combination of Encorafenib and Cetuximab With or Without Alpelisib in Patients With Advanced BRAF-Mutant (BRAFm) ...

$ARRY - Array Biopharma Inc - Independent Analysis (2)

$ARRY - Array Biopharma Inc - Independent Analysis (2)

Technical Analysis on $

Array Biopharma waiting on approval for skin cancer drugs

Array Biopharma waiting on approval for skin cancer drugs

Array Biopharma

Meet Gary - Array BioPharma

Meet Gary - Array BioPharma

When Gary was diagnosed with cancer, his doctors recommended a clinical trial. Hear his story in the latest video by

Meet Anne - Array BioPharma

Meet Anne - Array BioPharma

"You can't just sit back and be a spectator. You have to get into the fight and be a participant in this journey that we're all on.

$ARRY - Array Biopharma Inc - Independent Analysis

$ARRY - Array Biopharma Inc - Independent Analysis

Technical Analysis on $

ARRY Array BioPharma Inc  ARRY buy or sell Buffett read basic

ARRY Array BioPharma Inc ARRY buy or sell Buffett read basic

Buffett said: He saw all the stock earnings I think the final value of the investment does not need to see numbers only need to ...

Pfizer buys Array Biopharma for $48/share in cash

Pfizer buys Array Biopharma for $48/share in cash

Dow component Pfizer is buying

PropThink Interviews: Array BioPharma

PropThink Interviews: Array BioPharma

Ron Squarer, Chief Executive of

Array BioPharma Adds 10% on Positive Study Data for ARRY-520

Array BioPharma Adds 10% on Positive Study Data for ARRY-520

Array BioPharma

Meet the Scientist - Array BioPharma

Meet the Scientist - Array BioPharma

Go behind the scenes and "Meet the Scientist" with Allison Marlow, PhD, a medical writer and scientist at

News Update: Analyst Downgrades Array BioPharma, Inc; Shares Plummet (NASDAQ:ARRY)

News Update: Analyst Downgrades Array BioPharma, Inc; Shares Plummet (NASDAQ:ARRY)

Following

Overview of the NEMO Trial, Encorafenib for CRC

Overview of the NEMO Trial, Encorafenib for CRC

Dr. Victor Sandor talks about the latest developments at